Page last updated: 2024-09-05

lenalidomide and etoposide

lenalidomide has been researched along with etoposide in 20 studies

Compound Research Comparison

Studies
(lenalidomide)
Trials
(lenalidomide)
Recent Studies (post-2010)
(lenalidomide)
Studies
(etoposide)
Trials
(etoposide)
Recent Studies (post-2010) (etoposide)
3,5327252,85018,3063,6934,900

Protein Interaction Comparison

ProteinTaxonomylenalidomide (IC50)etoposide (IC50)
nuclear receptor coactivator 1 isoform 1 [Homo sapiens]Homo sapiens (human)1.153
nuclear receptor coactivator 3 isoform aHomo sapiens (human)1.4284
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)3.187
Caspase-3Homo sapiens (human)1
DNA topoisomerase 2-betaHomo sapiens (human)0.4299
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)4.18

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (10.00)29.6817
2010's11 (55.00)24.3611
2020's7 (35.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Alousi, A; Anderlini, P; Andersson, B; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Körbling, M; McMannis, J; Nieto, Y; Popat, U; Qazilbash, M; Saliba, R; Shpall, E; Thandi, R; Thomas, S; Wang, M; Weber, D1
Mateos, MV; San-Miguel, JF1
Berthou, C; Eveillard, JR; Guillerm, G; Ianotto, JC; Tempescul, A1
Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L1
Chen, CI; Chu, CM; Cserti-Gazdewich, C; Jiang, H; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Rabea, A; Reece, DE; Tiedemann, R; Trudel, S; Tsang, R1
Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K1
Beaven, AW; Bejot, C; Bhattacharyya, P; Carini, C; Chow, KF; Donato, ML; Feldman, T; Gadaleta, G; Goy, A; Kdiry, S; Mato, AR; Pecora, AL; Protomastro, EA; Rowley, SD; Smith, J; Stives, S; Timberg, M; Valentinetti, M; Yang, X; Yannotti, KM1
Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL1
Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A1
Amrein, PC; Attar, EC; Avigan, D; Ballen, KK; Brunner, AM; DeAngelo, DJ; Ebert, BL; Fathi, AT; Hobbs, GS; Luptakova, K; McMasters, M; Rosenblatt, J; Sperling, AS; Steensma, DP; Stone, RM; Stroopinsky, D; Wadleigh, M; Washington, A; Werner, L1
Bishop, MR; Cohen, KS; Godfrey, JK; Karmali, R; Karrison, T; Kline, JP; Nabhan, C; Rapoport, AP; Smith, SM; Stadler, WM; Venugopal, P1
Ballen, K; Bhatt, S; Brunner, A; Burgess, M; Carr, SA; DeAngelo, DJ; Ebert, BL; Fell, G; Garcia, JS; Keshishian, H; Letai, A; Medeiros, BC; Neuberg, D; Sperling, AS; Stone, RM; Yilma, B1
Au-Yeung, R; Chan, TSY; Ip, AHW; Kwong, YL; Pang, AWK1
Chen, M; Chen, W; Jiang, Q; Li, T; Liu, Y; Peng, J; Shi, X; Wu, J; Xi, X; Yu, X; Zhang, S; Zhu, Y1
Anderson, KC; Badros, A; Beksac, M; Bladé, J; Caers, J; Cavo, M; Dimopoulos, MA; Dispenzieri, A; Einsele, H; Engelhardt, M; Fernández de Larrea, C; Gahrton, G; Gay, F; Hájek, R; Hungria, V; Jurczyszyn, A; Kröger, N; Kyle, RA; Leal da Costa, F; Leleu, X; Lentzsch, S; Mateos, MV; Merlini, G; Mohty, M; Moreau, P; Rasche, L; Reece, D; Richardson, PG; Rosiñol, L; Sezer, O; Sonneveld, P; Usmani, SZ; Van de Donk, NWCJ; Vanderkerken, K; Vesole, DH; Waage, A; Zamagni, E; Zweegman, S1
Beaupre, D; Chhabra, S; de Vos, S; Huang, DW; Kimball, AS; Kwei, K; Neuenburg, JK; Phillips, T; Ping, J; Popplewell, L; Staudt, LM; Wilson, WH; Wright, G1
Iida, S; Inagaki, H; Ishida, T; Ito, A; Iwasaki, H; Kusumoto, S; Masaki, A; Murase, T; Muto, R; Nakano, N; Sakamoto, Y; Takeshita, M; Tashiro, Y; Tokunaga, M; Ueda, R; Utsunomiya, A; Yonekura, K1
Dong, T; Jing, F; Song, W; Wang, L; Wang, Y; Xiao, S; Xue, H1

Reviews

3 review(s) available for lenalidomide and etoposide

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
How to treat a newly diagnosed young patient with multiple myeloma.
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Disease Management; Doxorubicin; Endpoint Determination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Molecular Diagnostic Techniques; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning

2009
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
    British journal of haematology, 2021, Volume: 194, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Disease Management; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasmacytoma; Prognosis; Transplantation, Autologous

2021

Trials

6 trial(s) available for lenalidomide and etoposide

ArticleYear
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
    British journal of haematology, 2014, Volume: 166, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Ifosfamide; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome

2014
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
    British journal of haematology, 2016, Volume: 173, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Treatment Outcome; Young Adult

2016
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.
    American journal of hematology, 2018, Volume: 93, Issue:2

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Analysis

2018
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
    Cancer, 2019, 06-01, Volume: 125, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rituximab; Translocation, Genetic; Treatment Outcome; Vincristine

2019
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
    American journal of hematology, 2020, Volume: 95, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Etoposide; Female; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitochondria; Mitoxantrone

2020
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:9

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Piperidines; Prednisone; Treatment Outcome; Vincristine

2021

Other Studies

11 other study(ies) available for lenalidomide and etoposide

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow; Combined Modality Therapy; Cyclams; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Ifosfamide; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Risk Factors; Thalidomide; Transplantation, Autologous; Treatment Failure; Vincristine

2009
ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.
    Annals of hematology, 2011, Volume: 90, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Prednisone; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous

2011
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
    Vnitrni lekarstvi, 2012, Volume: 58, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous

2012
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Injections, Spinal; Kaplan-Meier Estimate; Lenalidomide; Male; Meninges; Middle Aged; Multiple Myeloma; Orbit; Proportional Hazards Models; Pyrazines; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Spine; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine

2013
Myeloma presenting during pregnancy.
    Hematological oncology, 2014, Volume: 32, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous

2014
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
    Hematological oncology, 2016, Volume: 34, Issue:1

    Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult

2016
Unique evolution of angioimmunoblastic T cell lymphoma to Epstein-Barr virus-positive plasma cell myeloma.
    Annals of hematology, 2020, Volume: 99, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Etoposide; Herpesvirus 4, Human; Humans; Lenalidomide; Lymphoma, T-Cell; Male; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisolone; Vincristine

2020
Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report.
    Medicine, 2020, Oct-30, Volume: 99, Issue:44

    Topics: Abdominal Wall; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Examination; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Lenalidomide; Lymphoma, Large-Cell, Anaplastic; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Skin Neoplasms; Transplantation, Autologous; Vincristine

2020
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    British journal of haematology, 2021, Volume: 195, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; CD28 Antigens; Cyclophosphamide; DNA Copy Number Variations; Doxorubicin; Etoposide; Female; Genes, p53; Hematopoietic Stem Cell Transplantation; Humans; INDEL Mutation; Kaplan-Meier Estimate; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mutation; Nitrosourea Compounds; Polymorphism, Single Nucleotide; Prednisolone; Prednisone; Prognosis; Receptors, CCR4; Vincristine; Vindesine

2021
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
    Hematological oncology, 2022, Volume: 40, Issue:4

    Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Etoposide; Frail Elderly; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednisone; Retrospective Studies; Rituximab

2022